Heimans J J, Wagstaff J, Schreuder W O, Wolbers J G, Baars J W, Polman C H, Scharenberg J G, Scheper R J, Palmer P A, Franks C R
Department of Neurology, Free University Hospital, Amsterdam, The Netherlands.
Surg Neurol. 1991 Mar;35(3):244-7. doi: 10.1016/0090-3019(91)90079-o.
A 42-year-old man developed leptomeningeal carcinomatosis 6 years after treatment of a malignant melanoma. He was treated with two courses of recombinant interleukin-2, administered as a continuous intraventricular infusion (6 X 10E5 U/24 h) during 5 days. During the first day of the first course he also received 5 X 10E9 lymphokine-activated killer cells intraventricularly. This gave rise to a severe elevation of intracranial pressure, with headaches and meningismus. During the second course no LAK cells were administered. This course was tolerated much better. The neurological status did not change during the treatment. Recombinant interleukin-2 levels were maintained at about 300 U/mL during both courses.
一名42岁男性在恶性黑色素瘤治疗6年后发生柔脑膜癌病。他接受了两个疗程的重组白细胞介素-2治疗，通过脑室内持续输注（6×10⁵单位/24小时），持续5天。在第一个疗程的第一天，他还脑室内注射了5×10⁹个淋巴因子激活的杀伤细胞。这导致颅内压严重升高，出现头痛和颈项强直。在第二个疗程中未注射LAK细胞。这个疗程的耐受性要好得多。治疗期间神经状态未改变。两个疗程中重组白细胞介素-2水平均维持在约300 U/mL。
